Enhance hepatic differentiation of human Wharton's jelly–derived mesenchymal stromal cells by using sodium butyrate pre-treated

Enhance hepatic differentiation of human Wharton's jelly–derived mesenchymal stromal cells by using sodium butyrate pre-treated

Poster Abstract Presentations assessed the feasibility of using gamma irradiation to obtain pathogen-reduced hPL and reported low impacts on the poten...

276KB Sizes 0 Downloads 35 Views

Poster Abstract Presentations assessed the feasibility of using gamma irradiation to obtain pathogen-reduced hPL and reported low impacts on the potency for cell expansion. Methods, Results & Conclusion: In this study, we validated the efficacy of gamma irradiation for virus inactivation. Four model viruses (BVDV, Reo3, HSV1, MMV) were chosen, per ICH/EMA guidelines, to represent a range of viruses with different genome, structure, size, and sensitivity to various chemical and physical agents. The virus spiked hPLs were gamma irradiated and the mean values of viral titers showed over 4 log10 reductions across all model viruses. The results demonstrated gamma irradiation is an effective viral reduction procedure for hPL. To assess the impacts of gamma irradiation on the long-term stability of hPL performance, we analyzed UltraGROTM GI series up to one year after gamma irradiation. The results showed growth factors still retained comparable levels to the non-irradiated hPLs. Mesenchymal stromal cells (MSC) cultured with gamma-irradiated hPLs for more than three passages showed similar profiles as with the corresponding non-irradiated hPLs in respect of growth rate, morphology, immunophenotype, trilineage differentiation potency, and immunosuppressive properties. 275 ENHANCE HEPATIC DIFFERENTIATION OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STROMAL CELLS BY USING SODIUM BUTYRATE PRE-TREATED W. Panta1, T. Yoisungnern1, S. Imsoonthornruksa1, S. Suksaweang2, M. Ketudat-Cairns1 & R. Parnpai1 1 Embryo Technology and Stem Cell Research Center and School of Biotechnology, Agricultural Technology, Nakhon Ratchasima, Thailand, 2 Pathology and Laboratory Medicine, Institute of Medicine, Suranaree University of Technology, Muang, Nakhon Ratchasima, Thailand Background & Aim: Human Wharton’s jelly derived mesenchymal stromal cells (hWJ MSCs) of umbilical cord tissue are a richest and more attractive source for stem cell based therapy. Despite of their ability to undergo selfrenewal, they also differentiate into all mesenchyme and some non mesenchyme tissues, including hepatocytes. This study, we differentiated hWJ MSCs into hepatocyte like cells by using sodium butyrate (NaB) pre treated with epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) supplementation. Methods, Results & Conclusion: Hepatic differentiation of hWJ MSCs was induced with 3 step differentiation protocol. The differentiated cells were examined for the expression of hepatic specific markers and hepatocyte function by using immunocytochemistry, real time reverse transcriptase polymerase chain reaction (RT PCR) and Periodic acid Schiff (PAS) staining. Before hepatic differentiation of hWJ MSCs, we identified embryonic definitive endodermal cells by using RT PCR, which increase of CXCR4 mRNA level, after NaB pre treated along with EGF and bFGF supplementation. Hepatic differentiation of hWJ MSCs by using NaB pre treated along with EGF and bFGF supplementation, the differentiated hWJ MSCs performed high hepatic specific markers at gene and protein levels, and increased signal of glycogen storage accumulation. Our result indicate that hWJ MSCs are able to differentiate into hepatocyte like cells by inducing of hepatic differentiation medium and NaB pre treated with EGF and bFGF supplementation. Therefore, the differentiated hWJ MSCs to hepatocyte like cells by inducing of NaB pre treated with EGF and bFGF condition could represent an alternative source of end stage of liver diseases. 276 SAFETY ISSUES OF PERIBULBAR INJECTION OF UMBILICAL CORD MESENCHYMAL STEM CELL (UC-MSC) IN PATIENTS WITH RETINITIS PIGMENTOSA C. Mangunsong12, B. Putera3, R. Haifa3, M. Suwandjaja2, A. Sharina1, M.B. Sasongko2 & Y.W. Wirohadidjojo2 1 JEC Hospital, Tangerang, Indonesia, 2Gadjah Mada University, Yogyakarta, Yogyakarta, Indonesia, 3Prodia Stemcell Indonesia, Jakarta, Indonesia Background & Aim: Hereditary retinal dystrophies, specifically retinitis pigmentosa (RP) are clinically and genetically heterogeneous diseases affecting primarily retinal cells and retinal pigment epithelial cells with blindness as a final outcome1. Retinitis pigmentosa is the term given to a set of hereditary retinal diseases that feature degeneration of rod and cone photoreceptors2. Typical symptoms include night blindness followed by decreasing visual fields, leading to tunnel vision and eventually legal blindness or, in many cases, complete blindness3. The worldwide prevalence of retinitis pigmentosa is about 1 in 4000 for a total of more than 1 million aff ected individuals. The disease can be inherited as an autosomal-dominant

S83

(about 30 40% of cases), auto somal-recessive (50 60%), or X-linked (5 15%) trait4. This disease is no hope no option treatment. Recent preclinical studies and clinical trials suggest cells-based therapy for the treatment of retinal degenerative diseases5. Cell-based therapy seems to be a promising strategy in Retinitis Pigmenotosa as it has the potential to regenerate new photoreceptors or retinal pigment epithelial (RPE) cells. Several types of stem cells had been investigated. However, in vivo studies showed that the cells from human umbilical corfd tissue appears to be the most effective in many diseases6-7 The purpose of this study is to evaluate of the safety of peribulbar injection of umbilical cord mesenchymal stem cells in patients with retinitis pigmentosa by a prospective, multi-center, randomized clinical trial. Methods, Results & Conclusion Methods: This study was conducted on 18 eyes of 18 volunteers with retinitis pigmentosa, The cells delivery with peribulbar injection method. Clinical examinitation, visus and fundus examination, multifocal electroretinography were performed before and after an peribulbar injection of approximately one-million UC-MSC. The patients were followed in 1 hour, 24 hours and 1 month for safety evaluation. Results: There are adverse events, like edema under the eyes, were observed in eyes all patients 1 hour after transplantation of UC-MSCs. The edema will disappear within 24 hours. These patients reported improvements in perception of the light and visus after one week Conclusion: Peribulbar injection of umbilical cord mesenchymal stem cells in eyes in patient with retinitis pigmentosa can occur edema under the eye which disappear within 24 hours.

1 hour and 24 hours after injection the cells

1 hour and 24 hours after injection the cells 277 CARTILAGE REGENERATION BY AUTOLOGOUS ADIPOSEDERIVED MESENCHYMAL STEM CELLS FOR THE TREATMENT OF OSTEOARTHRITIS Y. Jiang1, S. Iwata2, C. Yang1, K. Shirakawa3,1 & T. Matsuoka4 1 R&D, STEMCELL Co., Ltd., Tokyo, Japan, 2Riso Clinic, Tokyo, Japan, 3 Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan, 4CEO, STEMCELL Co., Ltd., Tokyo, Japan Background & Aim: Osteoarthritis (OA) is a degenerative joint disease mainly caused by wear and tear of the cartilage cushion between joints.